{"id":31949,"date":"2025-05-08T17:29:00","date_gmt":"2025-05-08T11:59:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31949"},"modified":"2025-05-08T15:01:22","modified_gmt":"2025-05-08T09:31:22","slug":"medtech-news-for-teleflex-livanova-roche","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche","title":{"rendered":"Teleflex Receives FDA 510(k) Clearance to Expand Use of QuikClot Control+\u2122; Edwards Wins FDA Nod for TAVR Use in Asymptomatic Aortic Stenosis; LivaNova Announces Positive 12-Month Results from OSPREY Study in Moderate to Severe OSA; Lipogems Completes Final Patient Visit in ARISE 1 Knee Osteoarthritis Trial; Roche Launches Advanced Elecsys PRO-C3 Test for More Accurate Liver Fibrosis Grading; iRhythm Introduces Zio\u00ae Long-Term ECG Monitoring in Japan, Enhancing AI-Driven Arrhythmia Detection"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1cb5c75d447\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1cb5c75d447\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#Teleflex_Secures_FDA_510k_Clearance_for_Broader_Use_of_QuikClot_Control%E2%84%A2_Hemostatic_Device\" >Teleflex Secures FDA 510(k) Clearance for Broader Use of QuikClot Control+\u2122 Hemostatic Device&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#Edwards_TAVR_Therapy_Gained_FDA_Approval_for_Asymptomatic_Severe_Aortic_Stenosis_Patients\" >Edwards\u2019 TAVR Therapy Gained FDA Approval for Asymptomatic Severe Aortic Stenosis Patients&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#LivaNova_Released_12-Month_OSPREY_Study_Data_Showing_Strong_and_Lasting_Effects_in_Moderate_to_Severe_Obstructive_Sleep_Apnea\" >LivaNova Released 12-Month OSPREY Study Data Showing Strong and Lasting Effects in Moderate to Severe Obstructive Sleep Apnea&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#Lipogems_Announced_Last_Patient_Last_Visit_for_Arise_1_Knee_Osteoarthritis_Trial\" >Lipogems Announced Last Patient Last Visit for Arise 1 Knee Osteoarthritis Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#Roche_Launched_the_Elecsys_PRO-C3_Test_to_Improve_Accuracy_in_Evaluating_Liver_Fibrosis_Severity\" >Roche Launched the Elecsys PRO-C3 Test to Improve Accuracy in Evaluating Liver Fibrosis Severity&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\/#iRhythm_Launched_the_Zio%C2%AE_Long-Term_Continuous_Monitoring_Service_in_Japan_as_Part_of_the_Zio%C2%AE_ECG_Recording_and_Analysis_System_Advancing_AI-Powered_Arrhythmia_Detection\" >iRhythm Launched the Zio\u00ae Long-Term Continuous Monitoring Service in Japan as Part of the Zio\u00ae ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-teleflex-secures-fda-510-k-clearance-for-broader-use-of-quikclot-control-hemostatic-device-nbsp\"><span class=\"ez-toc-section\" id=\"Teleflex_Secures_FDA_510k_Clearance_for_Broader_Use_of_QuikClot_Control%E2%84%A2_Hemostatic_Device\"><\/span><strong>Teleflex Secures FDA 510(k) Clearance for Broader Use of QuikClot Control+\u2122 Hemostatic Device&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 30, 2025, Teleflex Incorporated, a global leader in medical technologies, announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded Indications for Use of its QuikClot Control+\u2122 Hemostatic Device. The clearance extended the device\u2019s application to include all grades of internal and external bleeding. Previously, the QuikClot Control+\u2122 Device was cleared for the temporary control of class III and IV internal organ space bleeding, severely bleeding surgical wounds, mild to moderate bleeding in cardiac procedures, and bleeding from bone surfaces following sternotomy.<\/p>\n\n\n\n<p><em>\u201cBleeding remains a major contributor to mortality and morbidity in the United States,\u201d said Kevin Robinson, President and General Manager, Anesthesia and Emergency Medicine, Teleflex. \u201cUncontrolled, disruptive bleeding can significantly impact the clinical and economic outcomes of surgery. The expanded indication for the QuikClot Control+\u2122 Device portfolio allows us to target more procedures where fast, effective control of bleeding could benefit patients, clinicians, and health systems. Our primary focus remains on trauma, but this expanded indication will also support procedures in general surgery, gynecologic surgery, orthopedic surgery, and other areas. We estimate that these additional clinical spaces add more than $150 million to our serviceable addressable market in the United States.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cReal-world evidence was leveraged by Teleflex to obtain FDA clearance for this clinically important, expanded indication,\u201d said Michelle Fox, Corporate Vice President and Chief Medical Officer, Teleflex. \u201cThis means we are able to bring the technology of the QuikClot Control+\u2122 Device portfolio to more clinicians who will benefit from its ability to provide improved bleeding control for all grades of bleeding, from surgery to resuscitation.\u201d&nbsp;<\/em><\/p>\n\n\n\n<p>To support the labeling change, Teleflex relied on real-world evidence (RWE) derived from a retrospective, statistically powered observational study involving 603 emergency, trauma, and surgical patients. The study evaluated the safety and effectiveness of the QuikClot Control+\u2122 Device in managing all grades of bleeding across various anatomical sites during surgical procedures and injury-related bleeding. This RWE, which included a diverse patient population from multiple locations across the U.S., contributed to the FDA\u2019s decision to grant clearance for expanded indications. Following this approval, the QuikClot Control+\u2122 Hemostatic Device became indicated in the U.S. for the temporary control of external and identifiable internal bleeding, ranging from mild to life-threatening levels.<\/p>\n\n\n\n<p>In the European Union, the QuikClot Control+\u2122 Hemostatic Device was indicated for the temporary control of internal and external bleeding, including mild, moderate, severe, and traumatic bleeding resulting from injuries or surgical wounds. It was commercially launched in the EU in 2024.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/hemostats-market\"><strong>Hemostats Market Report<\/strong><\/a>\u201d, the global Hemostats market was valued at <strong>USD 3.64 billion<\/strong> in 2023, growing at a <strong>CAGR of 5.72%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 5.07 billion<\/strong> by 2030. The Hemostats market is slated to witness prosperity owing to factors such as the increasing number of surgical procedures, the growing focus on blood loss management during surgeries, emphasis on improving the safety and usability of hemostats for end users along with technological advancements are expected to result in appreciable revenue growth in the hemostats market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-edwards-tavr-therapy-gained-fda-approval-for-asymptomatic-severe-aortic-stenosis-patients-nbsp\"><span class=\"ez-toc-section\" id=\"Edwards_TAVR_Therapy_Gained_FDA_Approval_for_Asymptomatic_Severe_Aortic_Stenosis_Patients\"><\/span><strong>Edwards\u2019 TAVR Therapy Gained FDA Approval for Asymptomatic Severe Aortic Stenosis Patients&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 01, 2025, Edwards Lifesciences announced that the U.S. Food and Drug Administration (FDA) approved its transcatheter aortic valve replacement (TAVR) therapy, specifically the SAPIEN 3 platform, for the treatment of severe aortic stenosis (AS) in patients without symptoms. This marked the first FDA approval of a TAVR therapy for use in asymptomatic individuals.<\/p>\n\n\n\n<p>The approval of the SAPIEN 3 platform, which includes the SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA valves, was supported by pivotal findings from the EARLY TAVR trial. The trial showed that asymptomatic severe AS patients who were treated with Edwards\u2019 TAVR experienced significantly better outcomes than those who received the standard guideline-recommended approach of clinical surveillance or watchful waiting.<\/p>\n\n\n\n<p><em>\u201cThere is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend \u2018watchful waiting\u2019 until symptoms develop,\u201d said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. \u201cAs we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became symptomatic in sudden and unpredictable ways, underscoring the importance of early evaluation by a heart team to improve patient outcomes and benefit the healthcare system.\u201d<\/em><\/p>\n\n\n\n<p><em>&#8220;This approval is a powerful opportunity to streamline patient care and improve the efficiency of the healthcare system,\u201d said Larry Wood, Edwards\u2019 corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. \u201cWe are proud to partner with leading physicians to advance our knowledge of this deadly disease with high quality science and optimize the treatment pathway for patients.\u201d<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/transcatheter-aortic-valve-replacement-market\"><strong>Transcatheter Aortic Valve Replacement\/Implantation Market Report<\/strong><\/a>,\u201d the global transcatheter aortic valve devices market was valued at <strong>USD 3.23 billion<\/strong> in 2023, growing at a <strong>CAGR of 15.41% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 7.64 billion<\/strong> by 2030. The demand for transcatheter aortic valve replacement devices is primarily being boosted by the increasing prevalence of aortic stenosis disorder, rise in cardiovascular disorders, increasing demand for TAVR procedures, increasing prevalence of aortic regurgitation and the technological advancements pertaining to the transcatheter aortic valve replacement arena which are expected to increase in the product demand thereby contributing in the growth of the transcatheter aortic valve replacement devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-livanova-released-12-month-osprey-study-data-showing-strong-and-lasting-effects-in-moderate-to-severe-obstructive-sleep-apnea-nbsp\"><span class=\"ez-toc-section\" id=\"LivaNova_Released_12-Month_OSPREY_Study_Data_Showing_Strong_and_Lasting_Effects_in_Moderate_to_Severe_Obstructive_Sleep_Apnea\"><\/span><strong>LivaNova Released 12-Month OSPREY Study Data Showing Strong and Lasting Effects in Moderate to Severe Obstructive Sleep Apnea&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 07, 2025, LivaNova PLC, a leading medical technology company, announced 12-month top-line data from its OSPREY randomized controlled trial (RCT), which evaluated the aura6000\u2122 System for treating moderate to severe obstructive sleep apnea (OSA). At the 12-month mark, 65% of patients in the treatment arm were responders, those achieving at least a 50% reduction in baseline apnea-hypopnea index (AHI) and reaching an AHI below 20. The trial employed proximal hypoglossal nerve stimulation (p-HGNS), which used six electrodes on the proximal hypoglossal nerve trunk, enabling broader airway control and personalized titration.<\/p>\n\n\n\n<p>Previously, the company announced that OSPREY met its primary and secondary endpoints at six months. Results continued to improve at 12 months, with a 68% median reduction in both AHI (from 34.3 to 11.0) and oxygen desaturation index (ODI) (from 34.9 to 11.1). Additionally, treated patients showed clinically meaningful improvements in sleep-related quality of life scores, namely the Epworth Sleepiness Scale (ESS) and Functional Outcomes of Sleep Questionnaire (FOSQ).<\/p>\n\n\n\n<p><em>&#8220;OSPREY is the first major multi-center randomized, controlled pivotal trial of hypoglossal nerve stimulation. Patients in the device stimulation group experienced a rapid onset of therapy with continued improvement over time,\u201d said Dr. Atul Malhotra, lead investigator for the study, who is also a professor of medicine at the University of California, San Diego School of Medicine anda&nbsp; sleep medicine specialist at UC San Diego Health. \u201cResponder rates in the treatment group were strong throughout the first year, with one in four patients responding on day one, 50% responding by month three, and 65% responding by the 12-month mark. In addition, patient-reported outcomes for daytime sleepiness and functional outcomes of sleep quality demonstrated meaningful improvement over the course of 12 months.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cThe OSPREY trial demonstrated rapid and sustained improvement for patients who received active proximal hypoglossal nerve stimulation, including those with severe obstructive sleep apnea, elevated body mass index, and high risk of complete concentric collapse,\u201d said Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova. \u201cThe OSPREY 12-month results further validate the potential of this therapy as a treatment alternative for the large and growing OSA population. With the strength of our clinical data, expertise of our neuromodulation team, and strategic growth opportunity ahead, we are eager to bring this innovation to patients.\u201d<\/em><\/p>\n\n\n\n<p>The baseline values for OSA severity and body mass index (BMI) in the OSPREY study reflected those typically seen in the general obstructive sleep apnea (OSA) population. Compared to other large-scale hypoglossal nerve stimulation (HGNS) trials that supported FDA approval, OSPREY enrolled patients with more severe OSA and higher BMI. Additionally, the study was intentionally designed to include patients with complete concentric collapse (CCC). According to a recently presented predictive algorithm, the OSPREY trial successfully enrolled a patient cohort with a CCC risk ratio representative of what is commonly observed in clinical practice.<\/p>\n\n\n\n<p>At the 12-month mark, response rates and reductions in the apnea-hypopnea index (AHI) among patients with predicted CCC risk were consistent with those observed across the overall study population, underscoring the robustness of the therapy\u2019s effectiveness. LivaNova completed its premarket approval submission to the U.S. FDA for the aura6000\u2122 System based on meeting OSPREY\u2019s primary safety and efficacy endpoints after six months of treatment. The company also provided interim 12-month data from the study to the FDA and indicated plans to submit the full dataset during the regulatory review process.<\/p>\n\n\n\n<p>The aura6000\u2122 System, an investigational implantable device for proximal hypoglossal neurostimulation, was undergoing clinical evaluation for treating adults with moderate to severe OSA. Notably, no serious device-related or procedure-related adverse events were reported throughout the OSPREY study.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/sleep-apnea-devices-market\"><strong>Sleep Apnea Devices Market Report<\/strong><\/a>\u201d, the global sleep apnea devices market was valued at <strong>USD 7.53 billion<\/strong> in 2023, growing at a <strong>CAGR of 6.26%<\/strong> during the forecast period from 2024 to 2030 to reach<strong> USD 10.82 billion<\/strong> by 2030. The demand for sleep apnea devices is primarily being boosted due to the increasing cases of sleep apnea and the rising population with obesity. Further, the rising adoption of advanced and innovative technologies, the rising awareness about sleep apnea devices, the increasing geriatric population, and the increasing product launches and approvals among others, thereby contribute to the overall growth of the sleep apnea devices market during the forecast period from 2022-2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lipogems-announced-last-patient-last-visit-for-arise-1-knee-osteoarthritis-trial\"><span class=\"ez-toc-section\" id=\"Lipogems_Announced_Last_Patient_Last_Visit_for_Arise_1_Knee_Osteoarthritis_Trial\"><\/span><strong>Lipogems Announced Last Patient Last Visit for Arise 1 Knee Osteoarthritis Trial<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 07, 2025, Lipogems announced the successful completion of the ARISE I U.S. FDA IDE Study, with the last patient&#8217;s final visit now completed. This milestone marked the conclusion of a crucial phase in the development of Lipogems as a treatment for knee osteoarthritis (OA) in patients who were not yet ready for or did not qualify for knee replacement surgery. The double-blinded, randomized controlled trial involved 173 subjects across 18 respected U.S. sites. The primary endpoints of the study assessed improvements in pain and function 12 months after injection. The efficacy and safety results from the ARISE studies were expected to be announced in late 2025.&nbsp;<\/p>\n\n\n\n<p>While the Lipogems device has been FDA-cleared for use in orthopaedics and arthroscopic surgery for 10 years, these studies represented the largest clinical trials conducted by the company. The ARISE I and II studies were designed to support Lipogems in obtaining a separate indication specifically for knee OA. The data collected would be analyzed in the following months to evaluate the safety and efficacy of Lipogems, focusing on how it improved pain and function in patients with mild to moderate knee OA.<\/p>\n\n\n\n<p><em>&#8220;We are thrilled to reach this significant milestone,&#8221; said Carl Llewellyn, Chief Executive Officer of Lipogems USA. &#8220;This accomplishment brings us one step closer to making Lipogems a mainstream treatment option for patients with knee osteoarthritis who historically have had limited options. The successful conclusion of this trial represents the hard work and dedication of our team, clinical sites, and the patients who have placed their trust in us.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/orthopedic-devices-market\"><strong>Orthopedic Device Market Report<\/strong><\/a>\u201d, the global orthopedic devices market was valued at <strong>USD 44.09 billion<\/strong> in 2023, growing at a <strong>CAGR of 4.78%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 57.79 billion<\/strong> by 2030. The orthopedic devices market is slated to witness increasing revenue owing to factors such as a growing population of people above the age of 65, a rise in the cases of bone disorders such as osteoarthritis and osteoporosis among others, increasing cases of occupational injuries and non-occupational injuries along with latest technological developments in healthcare technology are further expected to result in the appreciable revenue growth in the orthopedic devices market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-roche-launched-the-elecsys-pro-c3-test-to-improve-accuracy-in-evaluating-liver-fibrosis-severity-nbsp\"><span class=\"ez-toc-section\" id=\"Roche_Launched_the_Elecsys_PRO-C3_Test_to_Improve_Accuracy_in_Evaluating_Liver_Fibrosis_Severity\"><\/span><strong>Roche Launched the Elecsys PRO-C3 Test to Improve Accuracy in Evaluating Liver Fibrosis Severity&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 06, 2025, Roche announced the launch of its Elecsys\u00ae PRO-C3 test, a new diagnostic solution aimed at assessing the severity of liver fibrosis in patients showing signs of metabolic dysfunction\u2013associated steatotic liver disease (MASLD). Developed in collaboration with Nordic Bioscience, the test provided clinicians with a simple and efficient method for identifying patients with varying levels of liver fibrosis, enabling timely intervention and proper disease management.<\/p>\n\n\n\n<p>MASLD affected approximately 30% of the population and was one of the most prevalent causes of chronic liver disease in the developed world. Primarily caused by diabetes, obesity, and other cardiometabolic risk factors, the number of individuals living with MASLD is growing rapidly, posing a significant burden on patients and healthcare systems globally. Despite being responsible for around one in every 25 deaths worldwide, liver fibrosis linked to MASLD often remains asymptomatic until reaching advanced stages, often going undetected for years. If left unmanaged, it could lead to severe outcomes such as cirrhosis, liver cancer, and liver failure.<\/p>\n\n\n\n<p><em>&#8220;The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging, and management of liver fibrosis,&#8221; said Matt Sause, CEO of Roche Diagnostics. &#8220;With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies.&#8221;<\/em><\/p>\n\n\n\n<p>The Elecsys PRO-C3 test requires only a single assay, which delivers results in only 18 minutes on Roche\u2019s cobas\u00ae analysers. This streamlines the process compared to currently available tests and reduces costs. Used in combination with the ADAPT formula, which includes PRO-C3 levels, platelet count, age and diabetes status, it provides a clear assessment of the severity of fibrosis, including distinguishing between different severities such as significant fibrosis (\u2265F2), advanced fibrosis (\u2265F3), and cirrhosis (F4). This is crucial for determining the appropriate treatment pathway for patients and identifying those who are eligible for new and emerging therapies.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/liver-disease-diagnostics-market\"><strong>Liver Disease Diagnostics Market Report<\/strong><\/a>\u201d, the global liver disease diagnostics market was estimated to grow at a <strong>CAGR of 5.97%<\/strong> during the forecast period from 2024 to 2030. The demand for liver disease diagnostics is primarily being boosted by the increasing number of people with liver diseases, the rise in alcohol consumption, and bad eating habits, among others. Furthermore, the liver disease diagnostics market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the liver disease diagnostics market during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-irhythm-launched-the-zio-long-term-continuous-monitoring-service-in-japan-as-part-of-the-zio-ecg-recording-and-analysis-system-advancing-ai-powered-arrhythmia-detection-nbsp\"><span class=\"ez-toc-section\" id=\"iRhythm_Launched_the_Zio%C2%AE_Long-Term_Continuous_Monitoring_Service_in_Japan_as_Part_of_the_Zio%C2%AE_ECG_Recording_and_Analysis_System_Advancing_AI-Powered_Arrhythmia_Detection\"><\/span><strong>iRhythm Launched the Zio\u00ae Long-Term Continuous Monitoring Service in Japan as Part of the Zio\u00ae ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On May 01, 2025, iRhythm Technologies, Inc. announced the commercial launch of its Zio\u00ae long-term continuous ECG monitoring (LTCM) system in Japan, where it was introduced as the Zio\u00ae ECG Recording and Analysis System. The system provided up to 14 days of continuous, uninterrupted ECG monitoring and utilized a deep-learned artificial intelligence (AI) algorithm, which was approved by Japan\u2019s Pharmaceuticals and Medical Devices Agency (PMDA). This launch represented a significant advancement over other ambulatory cardiac monitoring options available in Japan, such as commonly used wired Holter monitors that only captured 24 to 48 hours of data, and other patch-based services that monitored for up to 7 days.<\/p>\n\n\n\n<p><em>\u201cWe are honored to introduce our AI-powered Zio ECG Recording and Analysis System that provides up to 14 days of continuous, uninterrupted cardiac monitoring to Japan, where we see a meaningful opportunity to help advance arrhythmia detection,\u201d said Quentin Blackford, President and Chief Executive Officer of iRhythm. \u201cTogether with our trusted distribution partner, Senko Medical Instrument, we are committed to expanding access to advanced cardiac monitoring that supports clinical excellence and aligns with Japan\u2019s dedication to high-quality, patient-centered care.\u201d<\/em><\/p>\n\n\n\n<p><em>\u201cThe Zio long-term continuous monitoring service offers a clinically validated approach to arrhythmia detection by combining advanced AI with expert clinical review to support accurate and timely diagnoses,\u201d said Dr. Mintu Turakhia, iRhythm Chief Medical Officer, Chief Scientific Officer, and EVP of Product Innovation. \u201cAs the need for effective long-term monitoring grows, we believe the introduction of Zio LTCM in Japan presents an opportunity to enhance patient care and support evolving clinical needs in cardiac monitoring\u2014an impact also recognized by the Japanese Heart Rhythm Society.\u201d<\/em><\/p>\n\n\n\n<p>The Zio\u00ae ECG Recording and Analysis System consisted of a prescription-only, patch-based ECG monitoring device (Zio monitor) and the ZEUS (Zio ECG Utilization Software) system. The Zio monitor, iRhythm\u2019s latest-generation ECG patch, was designed for comfortable, discreet wear and enabled up to 14 days of continuous ECG monitoring. It demonstrated 99% patient compliance and 99% analyzable data, providing high-quality, actionable insights.<\/p>\n\n\n\n<p>The system leveraged a PMDA-approved AI algorithm that detected 13 arrhythmia types, sinus rhythm, and artifacts, performing at the level of cardiologists. End-of-wear reports were reviewed by certified cardiographic technicians, achieving 99% physician agreement. The Zio system was associated with the highest diagnostic yield and lowest likelihood of retesting compared to other monitoring services, including 24- to 48-hour Holter monitoring. In clinical settings, the Zio LTCM service helped reduce misinterpretation of ECG data and improve clinical efficiency.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/cardiac-monitoring-system-market\"><strong>Cardiac Monitoring System Market Report<\/strong><\/a>\u201d, the global cardiac monitoring market size is estimated at <strong>USD 27.70 billion<\/strong> in 2025, and is expected to reach <strong>USD 35.53 billion<\/strong> by 2030, at a <strong>CAGR of 5.11% <\/strong>during the forecast period. The market for cardiac monitoring systems is primarily driven by the increasing prevalence of cardiovascular diseases, aging populations, and rising awareness of heart health. Advancements in technology, such as the integration of artificial intelligence and wearable devices, have enhanced the accuracy and convenience of monitoring. The demand for continuous, long-term monitoring solutions is growing due to the need for early detection of arrhythmias and other heart conditions. Additionally, the shift towards remote patient monitoring, along with the increasing adoption of telemedicine and digital health solutions, is propelling the market forward. Moreover, regulatory approvals and technological innovations are improving the effectiveness and accessibility of these systems, further boosting their market growth.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Teleflex Secures FDA 510(k) Clearance for Broader Use of QuikClot Control+\u2122 Hemostatic Device&nbsp; On April 30, 2025, Teleflex Incorporated, a global leader in medical technologies, announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded Indications for Use of its QuikClot Control+\u2122 Hemostatic Device. The clearance extended the [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":31989,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22249,20281,22542,2753,17021,16975,19556,21518,21393],"industry":[17226],"therapeutic_areas":[17242,17240,17506],"class_list":["post-31949","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cardiac-monitoring-system","tag-hemostats","tag-liver-disease-diagnostics","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-orthopedic-devices","tag-sleep-apnea-devices","tag-transcatheter-aortic-valve-devices","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-sleep-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Teleflex, LivaNova, Roche<\/title>\n<meta name=\"description\" content=\"Teleflex\u2019s QuikClot Control+; Edwards\u2019 TAVR Therapy; LivaNova\u2019s OSPREY Study Data; Lipogems\u2019 Arise 1 Knee Osteoarthritis Trial\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Teleflex, LivaNova, Roche\" \/>\n<meta property=\"og:description\" content=\"Teleflex\u2019s QuikClot Control+; Edwards\u2019 TAVR Therapy; LivaNova\u2019s OSPREY Study Data; Lipogems\u2019 Arise 1 Knee Osteoarthritis Trial\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-08T11:59:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Teleflex, LivaNova, Roche","description":"Teleflex\u2019s QuikClot Control+; Edwards\u2019 TAVR Therapy; LivaNova\u2019s OSPREY Study Data; Lipogems\u2019 Arise 1 Knee Osteoarthritis Trial","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Teleflex, LivaNova, Roche","og_description":"Teleflex\u2019s QuikClot Control+; Edwards\u2019 TAVR Therapy; LivaNova\u2019s OSPREY Study Data; Lipogems\u2019 Arise 1 Knee Osteoarthritis Trial","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-08T11:59:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche","name":"MedTech News | Teleflex, LivaNova, Roche","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche.png","datePublished":"2025-05-08T11:59:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Teleflex\u2019s QuikClot Control+; Edwards\u2019 TAVR Therapy; LivaNova\u2019s OSPREY Study Data; Lipogems\u2019 Arise 1 Knee Osteoarthritis Trial","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-teleflex-livanova-roche#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche.png","width":772,"height":482,"caption":"medtech-news-for-teleflex-livanova-roche"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/08150049\/medtech-news-for-teleflex-livanova-roche-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cardiac Monitoring System<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hemostats<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Liver Disease Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Orthopedic Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sleep Apnea Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Transcatheter Aortic Valve Devices<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cardiac Monitoring System<\/span>","<span class=\"advgb-post-tax-term\">Hemostats<\/span>","<span class=\"advgb-post-tax-term\">Liver Disease Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Orthopedic Devices<\/span>","<span class=\"advgb-post-tax-term\">Sleep Apnea Devices<\/span>","<span class=\"advgb-post-tax-term\">Transcatheter Aortic Valve Devices<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on May 8, 2025","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on May 8, 2025 5:29 pm","modified":"Updated on May 8, 2025 3:01 pm"},"featured_img_caption":"medtech-news-for-teleflex-livanova-roche","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31949"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31949\/revisions"}],"predecessor-version":[{"id":31953,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31949\/revisions\/31953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31989"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31949"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31949"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}